Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
A group of researchers from the annual meeting of the American Academy of Orthopedic Surgeons (AAOS) "analyzed the data and...
Read Full NewsLack of access to innovative and effective treatments compromises survival outcomes for many patients in Europe with multiple myeloma.
A large study links the use of e-cigarettes after smoking cessation to higher lung cancer incidence and mortality than complete nicotine abstinence.
Post hoc analysis of the MajesTEC-3 trial shows the efficacy of the teclistamab plus daratumumab combination in hard-to-treat patients with high cytogenetic and functional risk.
Guidelines on treating cancer fatigue offer little enthusiasm for methylphenidate and other stimulants. But a recent meta-analysis suggests the medications deserve a rethink.
1.
The pandemic had little impact on mental health symptoms.
2.
Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.
3.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
4.
Research identifies nearly 200 potential breast carcinogens in food packaging materials
5.
Specific suicidal patterns mark the highest risk.
1.
Practical Developments in Hematology in the Digital Era
2.
The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy
3.
Oncology Trials Roadmap: From Drug Discovery to Delivery and Patient Access
4.
Liquid Biopsy: A Revolutionary Tool for Early Detection and Monitoring of Colorectal Cancer
5.
Beyond the Blood: Expanding CAR T-Cell Therapy to Solid Tumors- A New Era of Precision Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge